Inovio Pharmaceuticals Stock News

I demonstrate why Pfizer is the best choice for dividend investors playing the Covid-19 vaccine theme.

Its experimental coronavirus vaccine has some of the best clinical data among the 167 candidates in development.

If you've been following the race to discover a coronavirus vaccine, it won't be any shock to hear that both Moderna Therapeutics (NASDAQ: MRNA) and Inovio Pharmaceuticals (NASDAQ: INO) are among the

Could this biotech stock be a major winner down the road?

Its experimental coronavirus vaccine has some of the best clinical data among the 167 candidates in development.

Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sinking 12.2% lower as of 11:16 a.m. EDT on Wednesday. This marked the second consecutive day of steep declines for the stock after Inovio's Q2 upd

During Q2, Inovio Pharmaceuticals's (NASDAQ: INO) reported sales totaled $267.19 thousand. Despite a 15.17% in earnings, the company posted a loss of $29.06 million. Inovio Pharmaceuticals collected $

Questions about its coronavirus vaccine candidate continue to weigh on the biotech stock.

Inovio did not get the government funding or pre-orders like its competitors did, so if it happens later, INO stock will respond positively The post Inovio Still Has a Chance to Break Out in a Big Way

Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3

On Wall Street, it seemed as though Tuesday would be a repeat of Monday, with strength in the Dow Jones Industrial Average (DJINDICES: ^DJI) coupled with weakness in the tech-heavy Nasdaq Composite.

Both Inovio and BionNTech announced that they are making headway in their coronavirus vaccine trials, and will be able to meet deadlines toward the end of the year or a the start of 2021. Yahoo Financ

Inovio Pharmaceuticals Inc. shares tumbled 22% Tuesday, a day after the company reported a wider-than-expected second-quarter loss and offered a limited...

Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3

What looked like another rotation day turned into something more negative.